Hèctor Corominas, Millan Ana Milena, Diaz-Torne Cesar
Arthritis Unit, Rheumatology and Autoimmune Diseases Department, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.
Mediterr J Rheumatol. 2020 Dec 28;31(4):384-388. doi: 10.31138/mjr.31.4.384. eCollection 2020 Dec.
The prognosis of patients with rheumatoid arthritis (RA) has improved substantially in the last two decades due to the appearance of biological therapies, but above all, due to the improvement in the strategy and management of the disease. Our goal in RA should be to achieve remission, or in its absence, the lowest inflammatory activity. Achieving remission will prevent from structural and functional damage highly associated with RA itself. Clinical remission is defined as the absence of significant signs and symptoms of inflammatory disease activity, as well as the abrogation of any signs of systemic inflammation. Currently, there are some controversies about remission. Which is the real remission? Which remission criteria should be used and when? Does clinical remission mean ultrasound remission? In the present review, we try to answer and put some light into it, focusing on clinical and ultrasound deep remission.
在过去二十年中,由于生物疗法的出现,尤其是疾病治疗策略和管理的改善,类风湿关节炎(RA)患者的预后有了显著改善。我们对RA的治疗目标应该是实现缓解,若无法实现缓解,则应达到最低炎症活动水平。实现缓解将预防与RA本身高度相关的结构和功能损害。临床缓解的定义是不存在炎症性疾病活动的显著体征和症状,以及任何全身炎症迹象的消除。目前,关于缓解存在一些争议。真正的缓解是什么?应该使用哪些缓解标准以及何时使用?临床缓解是否意味着超声缓解?在本综述中,我们试图回答这些问题并阐明相关情况,重点关注临床和超声深度缓解。